Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tse Lee

Pain Medicine Coral Springs, FL Medical Doctor

NPI 1922259928 CMS profile 313950

8880 Royal Palm Blvd Ste 103, Ste 103, Coral Springs, FL 33065

Open in the dashboard

General payments

$10,353

424 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tse Lee of Coral Springs, FL is reported in the CMS Open Payments database as having received $10,353 across 424 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $915 36
2024 General $1,001 25
2023 General $1,103 38
2022 General $1,255 49
2021 General $1,634 72
2020 General $1,764 98
2019 General $2,681 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tse Lee
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Tse Lee were reported at $915. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Tse Lee Pain Medicine median Middle half National median
2019 $2,681 $409 $115–$1,311 $163
2020 $1,764 $214 $66–$666 $114
2021 $1,634 $299 $84–$899 $132
2022 $1,255 $335 $103–$1,149 $149
2023 $1,103 $376 $114–$1,228 $160
2024 $1,001 $387 $115–$1,173 $164
2025 $915 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $3,620 105 payments
  2. Medtronic USA, Inc. $2,647 105 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $987 81 payments
  4. Vertos Medical, Inc. $332 5 payments
  5. Allergan Inc. $278 17 payments
  6. Boston Scientific Corporation $170 4 payments
  7. Nevro Corp. $166 5 payments
  8. West Therapeutics Development, LLC $158 9 payments
  9. Pfizer Inc. $158 13 payments
  10. Bioventus LLC $149 3 payments
  11. Other $1,689 77 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,332 423 payments
  2. Education $21 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $1,621 42 payments
  2. MYSTIM $1,520 53 payments
  3. SYNCHROMED Drug Infusion Systems $898 39 payments
  4. RELISTOR $817 72 payments
  5. SYNCHROMEDII $546 20 payments
  6. VANTA ADAPTIVESTIM $466 10 payments
  7. BOTOX $303 18 payments
  8. mild Device Kit $254 4 payments
  9. Accurian $214 9 payments
  10. SYNCHROMED Drug Infusion Systems $174 7 payments
  11. Other $3,656 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,007

Median for Interventional Pain Management: 1,220

Drug cost

$16,311

Median for Interventional Pain Management: $39,344

Branded share of claims

40.6%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 226 $5,540
Morphine Sulfate Er Morphine Sulfate Brand 67 $2,460
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 116 $1,533
Gabapentin Generic 125 $1,270
Fentanyl Generic 11 $1,098
Tramadol Hcl Generic 135 $1,034
Pregabalin Generic 55 $882
Oxycodone Hcl Generic 48 $717
Tizanidine Hcl Generic 55 $430
Baclofen Generic 14 $369

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$143,676

Of which drugs: $259

Medicare patients

115

Average age 75

Services billed

3,733

81 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 47%
Diabetes 35%
Chronic kidney disease 35%
Depression 33%
Osteoporosis 32%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 88 2,868 $259

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

424 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record